SCHEMBL2697482

SCHEMBL2697482

O=C(c1ccc(CN(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1)N1CCC2(CCN(Cc3cccs3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.48
USP2 O75604 2/20 0.48
CXCR4 P61073 2/20 0.48
CYP3A4 P08684 10/20 0.47
TSHR P16473 5/20 0.47
CYP2C19 P33261 4/20 0.47
CYP2C9 P11712 6/20 0.47
HIF1A Q16665 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
CHRM2 P08172 3/20 0.43
CHRM3 P20309 2/20 0.43
CYP1A2 P05177 3/20 0.42
CCR8 P51685 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2692073 0.88 CXCR4 (0.48) CYP2D6CXCR4CYP3A4TSHRCYP2C19
SCHEMBL2694538 0.85 CXCR4 (0.67) CYP2D6USP2CXCR4CYP3A4TSHR
SCHEMBL2695052 0.84 CXCR4 (0.54) CYP2D6CXCR4CYP3A4CYP2C19KCNH2
SCHEMBL2696551 0.84 CXCR4 (0.50) CYP2D6CXCR4CYP3A4CYP2C19CYP2C9
SCHEMBL2693787 0.84 CXCR4 (0.50) CYP2D6CXCR4CYP3A4CYP2C19CYP2C9
SCHEMBL2695789 0.84 CXCR4 (0.54) CYP2D6CXCR4CYP3A4CYP2C19KCNH2
SCHEMBL2693682 0.83 CXCR4 (0.67) CYP2D6USP2CXCR4CYP3A4TSHR
SCHEMBL2692430 0.83 CXCR4 (0.51) CYP2D6USP2CXCR4CYP3A4TSHR
SCHEMBL2695977 0.81 CXCR4 (0.60) CYP2D6USP2CXCR4CYP3A4TSHR
SCHEMBL2694543 0.81 CXCR4 (0.47) CYP2D6USP2CXCR4CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CYP2D6 2687/4885USP2 4876/4885CXCR4 1/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CYP2D6 2851/4885USP2 4840/4885CXCR4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.